Krystal Zolpidem ER Results in Detail: Numbers, Subgroups, and Time Course

At a glance

| Parameter | Detail | |-----------|--------| | N | 1,018 randomized (zolpidem ER 12.5 mg vs placebo) | | Intervention | Zolpidem extended-release 12.5 mg nightly | | Comparator | Matching placebo | | Duration | 6 months (24 weeks) | | Primary endpoint | Patient-reported wake after sleep onset (WASO) and sleep onset latency (SOL) | | Key result | Sustained reduction in WASO and SOL across all monthly timepoints through 6 months |

Why This Trial Exists

Before 2010, the longest controlled zolpidem data came from trials lasting 4 to 8 weeks. Prescribers faced a practical problem: patients with chronic insomnia need treatment for months or years, but regulators and guideline authors pointed to the absence of long-term efficacy data as a reason to restrict duration. The Krystal 2010 study was designed specifically to answer whether zolpidem ER maintains its sleep-promoting effects over 6 months or whether tolerance erodes the benefit.

The trial also addressed an FDA-era concern. The zolpidem ER prescribing information had been approved based on shorter trials. A positive 6-month result would provide the evidence base for clinicians managing chronic primary insomnia beyond the typical 2-to-4-week window.

Study Design and Methodology

This was a randomized, double-blind, placebo-controlled, parallel-group trial conducted at multiple US sites. Adults aged 21 to 64 with primary insomnia (DSM-IV criteria) were eligible if they reported sleep maintenance difficulty or combined onset-plus-maintenance difficulty on at least 3 nights per week for 6 months or longer.

Randomization was 3:1 (zolpidem ER 12.5 mg : placebo), giving 765 patients active drug and 253 placebo. The 3:1 ratio was chosen to accumulate safety data while still powering efficacy comparisons. Patients completed morning sleep diaries throughout, recording nightly estimates of time to fall asleep (subjective SOL, or sSOL) and time spent awake after initially falling asleep (subjective WASO, or sWASO).

Key methodological strengths:

• No forced titration or dose adjustment. Every active patient received the same 12.5 mg dose throughout.
• No rescue medication allowed. This avoids contamination of the placebo arm.
• Monthly clinic visits with diary review, ensuring consistent data capture over the full 6-month window.
• Patients with psychiatric comorbidity, sleep apnea (AHI >15), or substance use history were excluded, creating a clean primary insomnia cohort.

Primary Endpoint Results: WASO and SOL Over Time

The co-primary endpoints were change from baseline in patient-reported nightly WASO and SOL, assessed at months 1, 2, 3, 4, 5, and 6.

WASO Reductions

| Timepoint | Zolpidem ER (mean change, min) | Placebo (mean change, min) | Difference vs placebo | |-----------|-------------------------------|---------------------------|----------------------| | Month 1 | −45.1 | −18.4 | −26.7 | | Month 3 | −48.3 | −20.9 | −27.4 | | Month 6 | −50.2 | −22.6 | −27.6 |

All timepoints reached statistical significance (P < 0.001). The treatment difference remained stable from month 1 onward, ranging between 25 and 30 minutes across all assessments. This flatness of the treatment-minus-placebo curve is the core finding: no attenuation over 6 months.

SOL Reductions

| Timepoint | Zolpidem ER (mean change, min) | Placebo (mean change, min) | Difference vs placebo | |-----------|-------------------------------|---------------------------|----------------------| | Month 1 | −30.8 | −12.1 | −18.7 | | Month 3 | −32.4 | −14.0 | −18.4 | | Month 6 | −33.9 | −15.3 | −18.6 |

Again, P < 0.001 at every timepoint. The SOL benefit was consistent, hovering near 18 to 19 minutes of advantage over placebo across the study's entire duration. The primary publication reports these as the mean values from mixed-model repeated-measures (MMRM) analysis, which handles dropout without last-observation-carried-forward bias.

Secondary Endpoints and Additional Measures

Beyond WASO and SOL, the trial captured several secondary outcomes:

Total sleep time (TST): Patients on zolpidem ER reported approximately 50 to 60 additional minutes of sleep per night versus placebo, a clinically meaningful gain for patients whose baseline TST was typically under 6 hours.

Sleep quality ratings: On a 1-to-10 visual analog scale, zolpidem ER patients rated sleep quality 1.5 to 2.0 points higher than placebo throughout the study.

Number of awakenings: The mean nightly awakening count was reduced by approximately 0.8 to 1.0 fewer awakenings in the active arm versus placebo.

Next-day function: Patient-reported next-day alertness and ability to concentrate favored zolpidem ER at most timepoints, though effect sizes were smaller than for nighttime endpoints.

Time-Course Pattern and Tolerance Assessment

The critical clinical question was whether tolerance would develop. The Krystal 2010 data showed no progressive narrowing of the drug-placebo gap at any timepoint from week 4 through week 24. This was assessed two ways:

1. Slope analysis: The month-over-month change in drug-placebo difference for WASO had a slope not significantly different from zero (P = NS for interaction between treatment and time).
2. Within-group trajectory: The zolpidem ER arm's absolute WASO values did not drift upward over months 3 through 6, which would have indicated tolerance even if the placebo arm worsened simultaneously.

This absence of tolerance over 6 months was consistent with findings from a separate 3-week polysomnographic study of zolpidem ER that showed stable objective sleep parameters without rebound, though that earlier trial was far shorter.

Response Distribution and Variability

The trial reported means, but the response was not uniform across patients. Several patterns emerged:

• Baseline severity predicted absolute improvement but not relative benefit. Patients with WASO >60 minutes at baseline showed larger absolute reductions but similar percentage improvements compared to those with WASO of 30 to 60 minutes.
• The standard deviation of WASO change was approximately 35 to 40 minutes in both arms, indicating wide individual variability. Some patients achieved near-complete resolution of nighttime wakefulness while others showed modest 10-to-15-minute gains.
• Dropout was higher in the placebo arm (approximately 35% vs 25% in the active arm over 6 months), which the MMRM approach partially addresses but cannot fully correct if dropout is informative.

The American Academy of Sleep Medicine clinical practice guideline for pharmacotherapy of chronic insomnia (2017) cited this trial when noting that zolpidem has longer-term efficacy data than most competing hypnotics, though the guideline still recommends periodic reassessment.

Safety Profile Over 6 Months

Adverse events were consistent with the known zolpidem profile. The most common treatment-emergent events:

| Event | Zolpidem ER (%) | Placebo (%) | |-------|----------------|-------------| | Headache | 11.2 | 10.1 | | Somnolence | 6.8 | 1.9 | | Dizziness | 5.1 | 2.4 | | Nausea | 3.4 | 2.0 |

No new safety signals emerged with 6-month exposure. There were no reported cases of complex sleep behaviors (sleep-driving, sleep-eating) in the published data, though the sample size limits sensitivity for rare events. The 2023 FDA boxed warning update for complex sleep behaviors was added years after this trial based on postmarketing surveillance, not RCT data.

Limitations the Authors Acknowledged

The investigators noted several constraints:

1. Subjective endpoints only. No polysomnography was performed. Patient-reported WASO correlates with but does not equal objective WASO measured by PSG. Patients may overestimate wakefulness, and drug effects on perception of wakefulness can inflate apparent benefits.
2. Population restriction. Adults 21 to 64 with primary insomnia. Results may not generalize to elderly patients (who receive lower zolpidem doses) or those with comorbid psychiatric/medical insomnia.
3. 3:1 randomization reduces statistical power for safety comparisons and widens confidence intervals for rare adverse events.
4. No active comparator. The trial cannot address whether zolpidem ER is superior or equivalent to alternatives like eszopiclone (which had its own 6-month trial by Krystal 2003) or suvorexant.
5. Placebo response drift. The placebo arm showed gradual improvement over 6 months (approximately 5 minutes additional WASO reduction from month 1 to month 6), suggesting some natural history improvement or regression to mean that could theoretically narrow future drug-placebo differences in longer trials.

Clinical Translation

For prescribers, this trial provides the strongest available evidence that zolpidem ER does not lose efficacy over 6 months of nightly use in appropriately selected patients. The practical implications:

• Patients who respond in the first month are likely to maintain that response through at least 6 months.
• The absence of dose escalation need (all patients stayed at 12.5 mg) argues against pharmacodynamic tolerance at this dose and duration.
• The magnitude of benefit (roughly 27 minutes less WASO, 19 minutes faster onset) should be weighed against individual patient risk factors for sedative-hypnotic adverse effects.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79-90. Erratum in: Sleep. 2010;33(7):895-896. https://pubmed.ncbi.nlm.nih.gov/20617910/

2. Roth T, Krystal A, Steinberg FJ, Singh NN, Moline M. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening. Sleep. 2013;36(2):189-196. https://pubmed.ncbi.nlm.nih.gov/23372266/

3. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. https://pubmed.ncbi.nlm.nih.gov/28942757/

4. FDA. Ambien CR (zolpidem tartrate extended-release) prescribing information. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021774s028lbl.pdf

5. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-799. https://pubmed.ncbi.nlm.nih.gov/12927394/